StockData

Black Hawk Acquisition Corp (BKHA) stock

BKHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends November 30Also trades as BKHAR, BKHAU
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 6, 2026Score 5/30
$7.30+1.92 (+35.81%)

Close on Nov 13, 2026Market cap $30.32MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Aug 31, 2026

Valuation

Market cap
$30.32M
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
$1.30M

Trading

Previous close
$5.38
Open
$6.15
Day's range
$5.60 – $9.20
Volume
1,726,645
Average volume (20 days)
170,553
Beta (5 years)
0.26
52-week range
$3.70 – $23.00
RSI (14 days)
54.3
Volatility (1 year)
86.2%
Relative volume
36.64×
WACC
7.6%

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

PeriodBKHAS&P 500DifferenceBKHA per yearS&P 500 per year
1 month-41.5%-3.0%−38.5 pts
3 months-38.0%-2.8%−35.2 pts
Year to date-35.1%+11.5%−46.6 pts
1 year-34.8%+13.5%−48.3 pts

Three years at a glance

Fiscal years 2023 to 2025 and trailing twelve months, USD

Operating income

-$519.49K

Net income

$1.30M-37.7% YoY
Reported periodTrailing twelve months

Press releases

Releases Black Hawk Acquisition filed with the SEC as exhibits to Form 8-K or 6-K

  1. Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer
    Update
  2. Hawk Acquisition Corporation Amends Its Definitive Proxy Statement
    News
  3. Hawk Acquisition Corporation Amends Its Definitive Proxy Statement
    News
  4. Hawk Acquisition Corporation Welcomes Mr. Jonathan Ginsberg to Board
    News
  5. Hawk Acquisition Corporation Welcomes Mr. Jonathan Ginsberg to Board
    News
  6. Report of Independent Registered Public Accounting Firm (PCAOB ID: 206)
    News
All press releases and earnings

About Black Hawk Acquisition

Biological Products, (No Diagnostic Substances)

The company is a blank check entity established to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more operational businesses. It does not sell commercial products, manufacture goods, or provide traditional commercial services, and it does not serve standard retail or enterprise consumers. Instead, its sole operational endeavor consists of identifying, conducting due diligence on, and evaluating suitable acquisition target candidates seeking access to public capital markets, including pursuing a definitive business combination agreement with a therapeutics enterprise.

Company profile, executives and history

Black Hawk Acquisition stock: common questions

What is Black Hawk Acquisition's stock price?

BKHA closed at $7.30 on Nov 13, 2026, up 35.81% on the day. Over the past 52 weeks it traded between $3.70 and $23.00.

What is Black Hawk Acquisition's market cap?

Black Hawk Acquisition was worth $30.32M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.

Does Black Hawk Acquisition pay a dividend?

No. Black Hawk Acquisition has not paid a cash dividend over the last twelve months.

How has BKHA stock performed over the past year?

Including dividends, BKHA returned -34.8% over the past year, against +13.5% for the S&P 500.

Who are Black Hawk Acquisition's competitors?

Companies most similar to Black Hawk Acquisition by business, industry and size include GPLB, TIL, VISK, CPMV, CLLS.

See a number that looks wrong?